Literature Review: Distinguishing glycosylation patterns in proteins for the early detection of cancer.

7th May 2019
Glycosylation is a post-translational modification where a carbohydrate is added to a protein. Glycosylation of proteins serves a number of functions in a cell, including: improve protein folding, forming lipid anchors and cell-to-cell adhesion. While glycosylation of a protein can be vital for its function, any changes in the position or number of […]

Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme

30th April 2019
Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as […]

The Reusability of Aptamers for Affinity Chromatography

23rd April 2019
We have often shown that aptamers make ideal ‘capture reagents’ for use in target specific affinity chromatography. Their flexible structure makes aptamers ideally suited for the specific binding and controlled release of their target, even in the presence of complex matrixes such as cell lysates or plasma.

During the aptamer selection process, we can […]

Literature Review: Glycan Specific Aptamers for Early Cancer Detection

9th April 2019
Changes in the glycosylation pattern of cell surface and secreted glycoproteins are common in malignant transformations and cancer progression, (1).  Prostate-specific antigen (PSA), is a glycoprotein enzyme secreted by the prostate gland that is often used for diagnosing and predicting progression of prostate cancer in men.  Recent advances in the field of glycobiology […]

Aptamers to discriminate between proteins with Post Translation Modifications

2nd April 2019
Background:

Post Translational Modifications (PTM) are biochemical variations of cetain amino acids made to a protein after biosynthesis. These modifications diversify the proteome and play a fundamental role in regulation and targeting of proteins, their interactions with other molecules, as well as their structure, activity and function. Common types of post-translational modifications include phosphorylation, […]

Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Aptamer Stability

29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]

Portable Aptamer Based Sensor for Toxin Detection

9th August 2018 
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]

Aptamer-based Lab on chip for the rapid detection of food-borne pathogens

1st August 2018
Scientists from the Technical University of Denmark, led by  Krishna  Kant have published a new review in Biotechnology Advances including  aptamer-based approaches  for the rapid detection of food-borne pathogens.
Food borne diseases, caused by the consumption of foods contaminated with pathogens or their toxins, are one of the major burdens to public health, causing […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]